Evotec SE (EVO) Stock Analysis and Metrics

Evotec SE

NASDAQ: EVO

$1.95 ▼ -0.03 (-1.58%)

At close: Jul 24, 2026 · 3:51 PM UTC

Financial Ratios

Market Cap346.06 Mn

P/E-2.87

Div. Yield0.00

Total Debt (Qtr)453,619.45

Add ratio to table…

About

Evotec SE is a life science company that provides integrated drug discovery, preclinical development, and manufacturing services to partners in the pharmaceutical and biotechnology industry. The company operates a full service platform that spans target identification, lead optimization, process development, and both small molecule and biologic production. By combining disease area expertise with proprietary technologies such as molecular patient databases, induced pluripotent stem cell models, and multi omics platforms, Evotec enables its clients to advance drug candidates from early research through clinical supply.

Evotec generates revenue primarily through fee for service contracts and full time equivalent (FTE) based arrangements, which together accounted for about 79% of total group revenues in 2025 and 94% in 2024. In addition, the company earns milestone payments and, to a lesser extent, royalties when partnered programs achieve commercial success, with milestone contributions representing 1.2% of 2025 revenues and 0.4% of 2024 revenues. The company also expects future growth from commercial manufacturing of biologics as its contract development and manufacturing organization (CDMO) activities scale.

The company operates through the following segments.

• Just Evotec Biologics: This segment provides antibody discovery, molecular optimization, process and product design, cell line and media development, and continuous and semi continuous biomanufacturing under GMP for clinical and commercial supply, including the J. POD platform for flexible, scalable production.

• Discovery & Preclinical Development: This segment offers target identification and validation, hit identification, structural biology, medicinal chemistry, in vitro and in vivo biology, biomarker analysis, early formulation, and integrated services such as IND enabling programs, API manufacturing, and cyto toxicity assessment through the Cyprotex platform.

Evotec holds a differentiated position in the outsourced drug discovery and development market by offering a fully integrated platform that spans chemistry, biology, transcriptomics, proteomics, and iPSC based disease modeling across small molecules, biologics, and cell therapies. This breadth sets it apart from competitors such as Wuxi Apptec, Charles River Laboratories, Lonza, and Samsung Biologics, which typically focus on narrower segments of the value chain. The company’s proprietary technologies, including its molecular patient databases, PanOmics platform, and AI driven analytics, enable rapid, data rich decision making and help improve return on R&D investment for its partners.

Evotec’s customer base consists of large pharmaceutical companies, mid size and small biotechnology firms, academic research institutions, venture capital backers, and nonprofit foundations. Notable partners that each contributed more than 10% of group revenues include Bristol Myers Squibb and Sandoz, while other collaborations have involved Bayer, Novo Nordisk, Eli Lilly, and various universities and biotech start ups. The company also engages with contract research organizations and healthcare providers to expand its service offerings.

Investment Thesis

▲ Bull case

Evotec's strategic pivot toward technology licensing and asset-light biologics manufacturing through the Sandoz transaction unlocks a high-margin, scalable business model with significant long-term upside, which the market is underestimating. The deal delivers an upfront $350 million consideration, with potential for over $300 million in mid-term license and development revenues and royalty streams from up to 10 biosimilar molecules targeting a combined $92 billion in originator sales. This transforms Just-Evotec Biologics from a capital-intensive CDMO into a high-margin technology licensor, reducing capital intensity while unlocking sustained royalty streams that could meaningfully contribute to EBITDA beyond 2026. The market is underestimating the durability and scalability of this IP-driven model, which leverages Evotec's proprietary continuous manufacturing platform and cell line technology to enable partner-led manufacturing without Evotec bearing capital expenditure burdens, thereby improving margins and free cash flow conversion over the mid-term.
Evotec's strategic partnership engine in Discovery & Preclinical Development (D&PD) is generating tangible near-term catalysts that the market is overlooking, with up to four partnered assets expected to enter Phase II clinical trials in 2026. This progression is underpinned by validated AI-enabled platforms like E.INVENT and the molecular patient database, which have already driven over $200 million in combined order value tied directly to these platforms. The progression of assets from preclinical to clinical stages de-risks the pipeline and increases the probability of milestone and royalty payments, with cumulative potential milestone value exceeding EUR 16 billion and potential accumulated returns to 2028 exceeding EUR 500 million. The market is underestimating the near-term inflection in milestone visibility as these assets advance, which could meaningfully uplift revenue visibility and EBITDA conversion well before the mid-term outlook period.
Evotec's cost-out program is executing ahead of plan, with EUR 60 million of in-year structural cost reductions already secured for 2025 and an additional EUR 50 million in mid-term productivity measures underway, yet the market is underappreciating the operating leverage this creates as the Biologics business scales. Just-Evotec Biologics is already delivering over 100% year-over-year growth in non-Sandoz, non-DoD business, and the Sandoz transaction further enhances mix shift toward higher-margin, lower-capital-intensity technology licensing. As fixed costs decline and higher-margin technology and licensing revenues scale, operating leverage will drive EBITDA margin expansion beyond the current 8–12% mid-term target, potentially exceeding 20% EBITDA margins by 2027 as the business model shifts toward asset-light, IP-driven revenue streams.

Evotec's strategic pivot toward technology licensing and asset-light biologics manufacturing through the Sandoz transaction unlocks a high-margin, scalable business model with significant long-term upside, which the market is underestimating. The deal delivers an upfront $350 million consideration, with potential for over $300 million in mid-term license and development revenues and royalty streams from up to 10 biosimilar molecules targeting a combined $92 billion in originator sales. This transforms Just-Evotec Biologics from a capital-intensive CDMO into a high-margin technology licensor, reducing capital intensity while unlocking sustained royalty streams that could meaningfully contribute to EBITDA beyond 2026. The market is underestimating the durability and scalability of this IP-driven model, which leverages Evotec's proprietary continuous manufacturing platform and cell line technology to enable partner-led manufacturing without Evotec bearing capital expenditure burdens, thereby improving margins and free cash flow conversion over the mid-term.
Evotec's strategic partnership engine in Discovery & Preclinical Development (D&PD) is generating tangible near-term catalysts that the market is overlooking, with up to four partnered assets expected to enter Phase II clinical trials in 2026. This progression is underpinned by validated AI-enabled platforms like E.INVENT and the molecular patient database, which have already driven over $200 million in combined order value tied directly to these platforms. The progression of assets from preclinical to clinical stages de-risks the pipeline and increases the probability of milestone and royalty payments, with cumulative potential milestone value exceeding EUR 16 billion and potential accumulated returns to 2028 exceeding EUR 500 million. The market is underestimating the near-term inflection in milestone visibility as these assets advance, which could meaningfully uplift revenue visibility and EBITDA conversion well before the mid-term outlook period.
Evotec's cost-out program is executing ahead of plan, with EUR 60 million of in-year structural cost reductions already secured for 2025 and an additional EUR 50 million in mid-term productivity measures underway, yet the market is underappreciating the operating leverage this creates as the Biologics business scales. Just-Evotec Biologics is already delivering over 100% year-over-year growth in non-Sandoz, non-DoD business, and the Sandoz transaction further enhances mix shift toward higher-margin, lower-capital-intensity technology licensing. As fixed costs decline and higher-margin technology and licensing revenues scale, operating leverage will drive EBITDA margin expansion beyond the current 8–12% mid-term target, potentially exceeding 20% EBITDA margins by 2027 as the business model shifts toward asset-light, IP-driven revenue streams.

▼ Bear case

Evotec's Discovery & Preclinical Development (D&PD) segment remains structurally challenged by a prolonged downturn in early-stage biotech funding, with venture capital investment in discovery and preclinical stages remaining well below pre-pandemic levels and showing no meaningful recovery over the past two quarters. This environment continues to suppress demand for Evotec's transactional services, which constitute 30–40% of D&PD revenue, and despite improved proposal activity and stabilizing change orders, there is no clear evidence of a sustained demand recovery. The company's reliance on volatile biotech funding cycles exposes it to prolonged revenue weakness in D&PD, which has already declined 12% year-to-date, and management's optimism about a 2026 recovery lacks concrete leading indicators, making the segment a persistent drag on group performance.
Evotec's pivot to an asset-light biologics model via the Sandoz transaction introduces significant execution and counterparty risk, particularly regarding the realization of up to $300 million in mid-term license and development revenues and royalties from up to 10 biosimilar molecules. The success of this model is contingent on Sandoz's successful commercialization of those biosimilars, which faces substantial risks including pricing pressure, biosimilar uptake delays, patent litigation, and manufacturing scalability issues — risks that Evotec does not control. Furthermore, the company is transitioning from a CDMO model with predictable service revenues to a royalty-dependent model where revenues are back-ended and uncertain, increasing earnings volatility and making near-term guidance highly dependent on the execution of a single large partner, thereby increasing concentration risk.
Evotec's cost-out program, while ahead of plan with EUR 60 million in structural savings for 2025, is being achieved through organizational restructuring and operational tightening that may undermine long-term innovation capacity, particularly in D&PD where R&D spending has already been cut by 33% year-to-date. This reduction in R&D investment, while improving short-term profitability, risks eroding the scientific differentiation and platform leadership that underpin Evotec's value proposition, particularly in AI-driven drug discovery platforms. Over time, underinvestment in core technology development could weaken the company's ability to maintain competitive differentiation in AI-enabled drug discovery, making it harder to win and retain strategic partnerships — the very engine of its long-term financial upside — thereby undermining the sustainability of its mid-term margin expansion thesis.

Evotec's Discovery & Preclinical Development (D&PD) segment remains structurally challenged by a prolonged downturn in early-stage biotech funding, with venture capital investment in discovery and preclinical stages remaining well below pre-pandemic levels and showing no meaningful recovery over the past two quarters. This environment continues to suppress demand for Evotec's transactional services, which constitute 30–40% of D&PD revenue, and despite improved proposal activity and stabilizing change orders, there is no clear evidence of a sustained demand recovery. The company's reliance on volatile biotech funding cycles exposes it to prolonged revenue weakness in D&PD, which has already declined 12% year-to-date, and management's optimism about a 2026 recovery lacks concrete leading indicators, making the segment a persistent drag on group performance.
Evotec's pivot to an asset-light biologics model via the Sandoz transaction introduces significant execution and counterparty risk, particularly regarding the realization of up to $300 million in mid-term license and development revenues and royalties from up to 10 biosimilar molecules. The success of this model is contingent on Sandoz's successful commercialization of those biosimilars, which faces substantial risks including pricing pressure, biosimilar uptake delays, patent litigation, and manufacturing scalability issues — risks that Evotec does not control. Furthermore, the company is transitioning from a CDMO model with predictable service revenues to a royalty-dependent model where revenues are back-ended and uncertain, increasing earnings volatility and making near-term guidance highly dependent on the execution of a single large partner, thereby increasing concentration risk.
Evotec's cost-out program, while ahead of plan with EUR 60 million in structural savings for 2025, is being achieved through organizational restructuring and operational tightening that may undermine long-term innovation capacity, particularly in D&PD where R&D spending has already been cut by 33% year-to-date. This reduction in R&D investment, while improving short-term profitability, risks eroding the scientific differentiation and platform leadership that underpin Evotec's value proposition, particularly in AI-driven drug discovery platforms. Over time, underinvestment in core technology development could weaken the company's ability to maintain competitive differentiation in AI-enabled drug discovery, making it harder to win and retain strategic partnerships — the very engine of its long-term financial upside — thereby undermining the sustainability of its mid-term margin expansion thesis.

Segments [axis] Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Products and services [axis] Breakdown of Revenue (2025)

Segments [axis] Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Products and services [axis] Breakdown of Revenue (2025)

Segments [axis] Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password